Influence of ML-1 standardized mistletoe extract on the quality of life in head and neck cancer patients;Einfluss eines ML-1-normierten mistelextraktes auf die lebensqualität bei patienten mit kopf-hals-karzinomen

HNO

Volumn 54, Issue 4, 2006, Pages 277-286

  Steuer Vogt, M ^a   Bonkowsky, V ^b   Scholz, M ^a   Fauser, C ^a   Licht, K ^c   Ambrosch, P ^d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b KLINIKUM NÜRNBERG   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

EORTC QLQ C30 (V2) instrument; Head and neck squamous cell carcinoma; ML 1 standardized mistletoe preparation; Quality of life; Radiotherapy

Indexed keywords

VISCUM ALBUM EXTRACT; VISCUM ALBUM LECTIN;

ARTICLE; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; INSTRUMENT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OTORHINOLARYNGOLOGIC NEOPLASMS; PHYTOTHERAPY; PLANT EXTRACTS; PLANT PREPARATIONS; PLANT PROTEINS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RADIOTHERAPY, ADJUVANT; RIBOSOME INACTIVATING PROTEINS, TYPE 2; TOXINS, BIOLOGICAL;

EID: 33646239358     PISSN: 00176192     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00106-005-1318-y     Document Type: Article

References (26)

1. Allison PJ (2002) Alcohol consumption is associated with improved health-related quality of life in head and neck cancer patients. Oral Oncol 38: 81-86
2. Allison PJ, Guichard C, Gilain L (2000) A prospective investigation of dispositional optimism as a predictor of health-related quality of life in head and neck cancer patients. Qual Life Res 9: 951-960
3. Allison PJ, Locker D, Wood-Dauphinee S, Black M, Feine JS (1998) Correlates of health-related quality of life in upper aerodigestive tract cancer patients. Qual Life Res 7: 713-722
4. Barofsky I (1996) Cancer: Psychological aspects. In: Spilker B (ed) Quality of life and pharmaeconomics in clinical trials. Lippincott-Raven, Philadelphia, pp 993-1002
5. Berg PA, Stein GM (2001) Does mistletoe therapy influence the defense against epithelial tumors? A critical immunologic analysis. Dtsch Med Wochenschr 126: 339-345
6. Beuth J, Stoffel B, Ko HL, Jeljaszewicz J, Pulverer G (1995) Immunomodulating ability of galactoside-specific lectin standardized and depleted mistletoe extract. Arzneimittelforschung. 45: 1240-1242
7. Beuth J, Ko HL, Gabius HJ, Pulverer G (1991) Influence of treatment with the immunomodulatory effective dose of the beta-galactoside-specific lectin from mistletoe on tumor colonization in BALB/c-mice for two experimental model systems. In Vivo 5: 29-32
8. Bjordal K, de Graeff A, Fayers PM et al. (2000) A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer 36: 1796-807
9. Braun JM, Ko HL, Schierholz JM, Beuth J (2002) Standardized mistletoe extract augments immune response and down-regulates local and metastatic tumor growth in murine models. Anticancer Res 22: 4187-4190
10. Bullinger M (1996) Methoden zur Lebensqualitätsbewertung in der Onkologie. Forum DKG 11: 210-218
11. Edler L (2004) Mistel in der Krebstherapie: Fragwürdige Ergebnisse neuerer klinischer Studien. Dtsch Ärztebl 101: B39-B44
12. Ernst E, Schmidt K, Steuer-Vogt MK (2003) Mistletoe for cancer? A systematic review of randomized clinical trials. Int J Cancer 107: 262-267
13. Fayers P, Aaronson NK, Bjordal K, Sullivan M (1995) EORTC QLQ-C30 Scoring Manual. EORTC Study Group on Quality of Life, pp 1-46
14. Friess H, Beger HG, Kunz J, Funk N, Schilling M, Büchler MW (1996) Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial. Anticancer Res 16: 915-920
15. Grothey A, Düppe J, Hasenburg A, Voigtmann R (1998) Use of alternative medicine in oncology patients. Dtsch Med Wochenschr 123: 923-929
16. Hammerlid E, Bjordal K, Ahlner-Elmqvist Metal. (2001) A prospective study of quality of life in head and neck cancer patients. Part I: at diagnosis. Laryngoscope 111: 669-680
17. Heiny BM (1991) Additive Therapie mit standardisiertem Mistelextrakt reduziert die Leukopenie und verbessert die Lebensqualität von Patientinnen mit fortgeschrittenem Mammakarzinom unter palliativer Chemotherapie (VEC-Schema). Krebsmedizin 12: 1-14
18. Heiny BM, Albrecht V (1997) Komplementäre Therapie mit Mistellektin-1-normiertem Extrakt. Lebensqualitätsstabilisierung beim fortgeschrittenen kolorektalen Karzinom - Fakt oder Fiktion? Med Welt 48: 419-423
19. Joshi SS, Komanduri KC, Gabius S, Gabius HJ (1991) Immunotherapeutic effects of purified mistletoe lectin (ML-1) on murine large lymphoma. In: Gabius HJ, Gabius S (eds) Lectins and cancer. Springer, Berlin Heidelberg NewYork, pp 207-216
20. Maune S, Bosse F, Heissenberg MC, Schmidt C, Berens M, Kuchler T (2002) A concept for the assessment of quality of life in patients with carcinomas of the upper aerodigestive tract. HNO 50: 347-353
21. Miller M, Boyer MJ, Butow PN, Gattellari M, Dunn SM, Childs A (1998) The use of unproven methods of treatment by cancer patients. Frequency, expectations and cost. Support Care Cancer 6: 337-347
22. Osoba D, Aaronson N, Zee B, Sprangers M, te VA (1997) Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group. Qual Life Res 6: 103-108
23. Spilker B (1996) Introduction to the field of quality of life trials. In: Spilker B, ed.Quality of life and pharmaeconomics in clinical trials. Lippincott-Raven, Philadelphia, pp 1-10
24. Steuer-Vogt MK (2004) Mistletoe is a useful adjunct in cancer therapy - Contra part. Focus Altern Complement Ther 9: 15-18
25. Steuer-Vogt MK, Bonkowsky V, Scholz M, Arnold W (2002) Plattenepithelkarzinome des Kopf-Hals-Bereichs. Mistellektin-1-normierte Viscumtherapie. Dtsch Ärztebl 46: B2585-B2591
26. Steuer-Vogt MK, Bonkowsky V, Ambrosch P et al. (2001) The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients. a randomised controlled clinical trial. Eur J Cancer 37: 23-31